The Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance (PrIMAVeRa) project assembles a highly skilled and interdisciplinary consortium with complementary skills. The consortium comprises 13 Universities, research organisations, public bodies, and non-profit groups; 2 Small-and Medium sized Enterprises; and 3 EFPIA members. The consortium is coordinated by a non-profit vaccine development organisation, European Vaccine Initiative (EVI), with considerable experience in managing large and complex multi-partner consortia. All participants have collaborated successfully with industrial partners on several occasions and in many different contexts. The scientific leadership of PrIMAVeRa will be undertaken by Professor Marc Bonten from University Medical Center Utrecht (UMCU), one of Europe´s leading academic institutions in the area of AMR.
PrIMAVeRa includes leading European academic institutions in the fields of mathematical modelling of infectious diseases —UMCU, Danmarks Tekniske Universitet (DTU), Institut Pasteur (IP), UK Health Security Agency (UKHSA). It includes academic institutions and medical centres with expertise in clinical and epidemiological aspects of antimicrobial resistance —UMCU, Université de Genève (UNIGE), Università di Verona (UNIVR), Servicio Andaluz de Salud (SAS), Université Grenoble Alpes (UGA)—, as well as organisations with expertise in vaccine development —EVI, University of Oxford (UOXF)— and mAb —Instituto de Salud Carlos III (ISCIII), UGA. It includes public health research institutions —ISCIII, UKHSA, Kauno Klinikos (KK), The Federal State Scientific Institution Saint-Petersburg Scientific Research Pasteur Institute Of Epidemiology And Microbiology (SPPI)— with experience in epidemiology and strategies for AMR. Furthermore, several partners —Eberhard Karls Universität Tübingen (UT), UNIVR, SAS, Life Science Network (LSN)— bring well-established skills in establishing and managing sustainable data base platforms, while other partners —UKHSA, UOXF— bring considerable experience in health economics and cost-efficiency analysis.
The consortium includes SMEs with highly innovative bioinformatic tools and datasets (Ares) and an non-profit organisation (LSN) with proven track records in bringing bioinformatic solutions to application.